glp 1 agonists and inflammation GLP-1 drugs calm beyond diabetes weight loss The anti-inflammatory and immunological properties

December 2, 2025: Modest Growth for Ozempic Gastroparesis MDL There are now 2,947 active lawsuits in the MDL focused on claims involving GLP-1 drugs and intestinal conditions like gastroparesis

20,23 Cardiovascular outcomes Data from randomized clinical trials evaluating the effect of GLP-1RA on CV outcomes are limited

This is the other phase 2 trial of retatrutide in individuals with type 2 diabetes and overweight/obesity

2016;167(3):843-857.e814

NAION is rare in general, said Xu

therefore, patients and health care providers are often searching for additional strategies to promote weight loss, and certainly strategies to avoid or attenuate weight gain